Cerebral Palsy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Will be included in this study individuals with a medical diagnosis of spastic type CP.
Exclusion criteria
Exclusion criteria: Will be excluded individuals with progressive or neurodegenerative lesions will be excluded; Individuals with CP who are taking any drug that interferes with salivary secretion such as anticholinergics, neuroleptics or benzodiazepines for at least 72 hours prior to salivary collection; Or have undergone surgical procedures to control the external flow of saliva. Still, individuals who do not collaborate with the salivary collection have used antibiotics in the last month, present symptoms of fever, flu, body aches or diarrhea, or even an inflammatory condition on the oral mucosa as a cold sore.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expected outcome is the reduction in the level of inflammatory markers in saliva. The method used to verify the expected outcome will be the evaluation of the level of Interleukin 1beta, Interleukin 6, Interleukin 8, Interleukin 10, Tumor Necrosis Factor and Interleukin 12p70 in saliva. The parameter to be used to evaluate the occurrence of the outcome will be a reduction of at least 50% in the level of the inflammatory cytokines. Clinical evaluations and saliva collection will be performed before and after treatment for gingivitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| The expected outcome is the reduction of the degree of gingivitis. The method used to verify the expected secondary outcome will be the evaluation of the Gingival Index. The parameter to be used to evaluate the occurrence of the outcome will be the verification of a reduction of 50% in the measurements before and after periodontal treatment. | — |
Countries
Brazil
Contacts
Universidade Cruzeiro do Sul